This is an application for participation by the Long Island Jewish Medical Center as a primary member institution in the overall research activities of Cancer and Leukemia Group B (CALGB) - the NCI-sponsored consortium for cancer research. CALGB conducts randomized clinical trials requiring large scale case accession for testing new and innovative treatments of various types of human cancers in the adult and comparing the results with the best known standard therapies. In addition, studies on basic science of each cancer under investigation are conducted to improve the understanding of its pathophysiology. Emphasis is placed also on psychosocial as well as epidemiological aspects of each type of cancer. Because any one institution only has relatively small numbers of patients with various types of cancer under study, a consortium such as CALGB of like-minded investigators from 26 academic institutions enables, by pooling their respective patient populations, accession of larger numbers which are sufficient to conduct such studies. LIJ-based oncologists maintained an active role in this research process: (1) by proposing concepts for new studies in various types of cancers; (2) by entering cases to each protocol in a disciplined, systematic manner while strictly adhering to the principles of ethical conduct of research involving human subjects, and (3) by emphasizing availability of this research to segments of our society which may have been neglected in the past - women and minority populations. Treatment of each patient is delivered according to a specific protocol, good quality clinical data are collected throughout the period of each study and submitted to the CALGB Biostatistical Center for appropriate analysis and review. LIJ-based scientists then participate actively in group-wide review and discussion of the pooled data from these studies and in preparation of manuscripts summarizing the significance of these results. Thus, the major objective of developing improved methods of treatment of cancer is served by LIJ's participation in CALGB-sponsored research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011028-27
Application #
2085935
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-04-01
Project End
1998-03-31
Budget Start
1994-04-01
Budget End
1995-03-31
Support Year
27
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Long Island Jewish Medical Center
Department
Type
DUNS #
City
New Hyde Park
State
NY
Country
United States
Zip Code
11040
Ogino, Shuji; Liao, Xiaoyun; Imamura, Yu et al. (2013) Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. J Natl Cancer Inst 105:1789-98
Lichtman, S M; Hurria, A; Cirrincione, C T et al. (2012) Paclitaxel efficacy and toxicity in older women with metastatic breast cancer: combined analysis of CALGB 9342 and 9840. Ann Oncol 23:632-8
Smith, S M; Johnson, J; Cheson, B D et al. (2009) Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma 50:1606-17
Stinchcombe, Thomas E; Hodgson, Lydia; Herndon 2nd, James E et al. (2009) Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 4:1117-25
Blanke, Charles D; Rankin, Cathryn; Demetri, George D et al. (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-32
Bogart, Jeffrey A; Watson, Dorothy; McClay, Edward F et al. (2008) Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer 62:92-8
Paschka, Peter; Marcucci, Guido; Ruppert, Amy S et al. (2008) Wilms'tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol 26:4595-602
Chan, Jennifer A; Meyerhardt, Jeffrey A; Niedzwiecki, Donna et al. (2008) Association of family history with cancer recurrence and survival among patients with stage III colon cancer. JAMA 299:2515-23
Miller, Antonius A; Murry, Daryl J; Owzar, Kouros et al. (2007) Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101. J Clin Oncol 25:3055-60
Vokes, Everett E; Herndon 2nd, James E; Kelley, Michael J et al. (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 25:1698-704

Showing the most recent 10 out of 36 publications